v3.26.1
Segment Information - Summary Of Disaggregated Research And Development Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Dec. 31, 2025
Mar. 31, 2025
Revenue, Major Customer [Line Items]      
Personnel related and stock-based compensation $ 20,072 $ 16,988 $ 15,814
Other research and development expenses 30,395 29,687 23,901
Research and Development Expense, Total 95,726 86,599 70,886
Darovasertib      
Revenue, Major Customer [Line Items]      
External clinical development expenses 23,332 23,254 23,018
IDE397      
Revenue, Major Customer [Line Items]      
External clinical development expenses 3,515 3,432 3,741
IDE161      
Revenue, Major Customer [Line Items]      
External clinical development expenses 1,607 1,791 2,448
IDE849      
Revenue, Major Customer [Line Items]      
External clinical development expenses 4,765 6,908 423
IDE892      
Revenue, Major Customer [Line Items]      
External clinical development expenses 2,180 2,269 860
IDE034      
Revenue, Major Customer [Line Items]      
External clinical development expenses 6,808 837 38
IDE574      
Revenue, Major Customer [Line Items]      
External clinical development expenses $ 3,052 $ 1,433 $ 643